The American Journal of Managed Care3d
Next-Gen Strategies for Resistance in EGFR-Mutated Lung Cancer
Sabari, MD, which focused on the first-line approval of amivantamab (Ami; Rybrevant; Johnson & Johnson) plus lazertinib ...
In the US, young and middle-aged women are being diagnosed with lung cancer at higher rates than men
Susan Wojcicki, the late CEO of YouTube, had a message for the world just weeks before she passed away in August: “Lung ...
Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...
FierceBiotech9d
AstraZeneca, Daiichi share data behind Dato-DXd do-over amid 2nd bid for lung cancer approval
AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...
MRK: Sac-TMT Gets FDA Breakthrough Therapy Designation For EGFR-mutated Advanced Or Metastatic NSCLC
Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...
Cure Today12d
FDA Grants Breakthrough Therapy Designation to Sac-TMT for Some with NSCLC
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...
Targeted Oncology11d
FDA Grants Breakthrough Status to Sacituzumab Tirumotecan in EGFR+ NSCLC
The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.
Pharmabiz2d
Dizal announces positive pooled data of sunvozertinib in EGFR TKI-resistant NSCLC
Dizal announces positive pooled data of sunvozertinib in EGFR TKI-resistant NSCLC: Shanghai, China Friday, December 13, 2024, 18:00 Hrs [IST] Dizal, a biopharmaceutical company co ...
Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment
Merck ( MRK, Financials) stated that sacituzumab tirumotecan (sac-TMT) was designated a Breakthrough Therapy by the FDA for advanced or metastatic nonsquamous non-small cell lung cancer with epidermal ...